ArticleMenopause (New York, N.Y.)2019
A prospective study of inflammatory biomarker levels and risk of early menopause.
Article in Menopause (New York, N.Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Sex-related differences in markers of immune activation in virologically suppressed HIV-infected patients.Biology of sex differences · 2020Trial
- Association of Chemerin, follicle stimulating hormone, lipid profiles, and cardiometabolic indices with the premature ovarian insufficiency.Scientific reports · 2026Article
- Association between endometriosis and type and age of menopause: a pooled analysis of 279 948 women from five cohort studies.Human reproduction (Oxford, England) · 2025Article
- Inflammation and Ovarian Function in Reproductive-Aged Women.American journal of human biology : the official journal of the Human Biology Council · 2025Article
- Inflammation and olfactory loss are associated with at least 139 medical conditions.Frontiers in molecular neuroscience · 2024Article
- TNF-α and IFN-γ prestimulation enhances the therapeutic efficacy of human amniotic epithelial stem cells in chemotherapy-induced ovarian dysfunction.Inflammation and regeneration · 2023Article
- Premenstrual Disorders, Timing of Menopause, and Severity of Vasomotor Symptoms.JAMA network open · 2023Article
- Protein Biomarkers of Early Menopause and Incident Cardiovascular Disease.Journal of the American Heart Association · 2023Article
- The Aging Ovary and the Tales Learned Since Fetal Development.Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation · 2023Review
- Trauma, psychological distress and markers of systemic inflammation among US women: A longitudinal study.Psychoneuroendocrinology · 2022Article
- Association of Handgrip Strength with Diabetes Mellitus in Korean Adults According to Sex.Diagnostics (Basel, Switzerland) · 2022Article
- Paeoniflorin Alleviates Skeletal Muscle Atrophy in Ovariectomized Mice through the ERα/NRF1 Mitochondrial Biogenesis Pathway.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Association Between Laparoscopically Confirmed Endometriosis and Risk of Early Natural Menopause.JAMA network open · 2022Article
- Long-term exposure to particulate matter and roadway proximity with age at natural menopause in the Nurses' Health Study II Cohort.Environmental pollution (Barking, Essex : 1987) · 2021Article
- The Role of Oxidative Stress and Natural Antioxidants in Ovarian Aging.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveEarly menopause, the cessation of ovarian function before age 45, has consequences for fertility and cardiovascular health. Evidence from studies of women with autoimmune conditions and genetic studies supports a role for inflammation in early menopause, but the association of inflammatory markers and risk has not been directly evaluated.
methodsWe assessed the relation of the soluble fraction of tumor necrosis factor alpha receptor 2 (sTNFR2), C-reactive protein, interleukin-6 (IL6) levels with incident early menopause among Nurses' Health Study II participants who provided a premenopausal blood sample in 1996 to 1999. Cases (n = 328) were women reporting natural menopause between blood collection and age 45.Controls (n = 492) included (1) 328 women with menopause after age 47, matched 1:1 with cases on age at blood collection and other factors; and (2) 164 additional women with menopause after age 45.
resultsIn multivariable models comparing cases and n = 492 controls, we observed a significant association of sTNFR2 levels and risk of early menopause (P = 0.002). Compared with women with the lowest sTNFR2 levels, odds ratios (95% CIs) for quartiles 2 to 4 were 0.60 (0.38-0.95), 0.93 (0.61-1.43), and 1.40 (0.93-2.11). Results further adjusting for antimüllerian hormone levels were similar in magnitude, as were results from sensitivity analyses of matched cases and controls (n = 328 pairs), nonsmokers, and leaner women. C-reactive protein and IL6 levels were unrelated to risk.
conclusionsThe observation of lower risk of early menopause among women with moderate sTNFR2 levels compared with women with lower and higher levels warrants further prospective study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.